Strategic Investments & Collaborations Boost Global Transcatheter Valve Market Growth

Global transcatheter valve market size was $6,840 million in 2024 and is projected to grow at a CAGR of 15.7% during the forecast period (2025-2035). Large investments in R&D and global trials are accelerating, driven by venture capital firms increasing support for disruptive players such as CoreMedic, Boston Scientific, and JenaValve, driving market growth. For instance, in February 2025, CoreMedic secured additional funding in a Series B extension from MIG Capital AG, a leading German venture capital firm. The funding will accelerate the clinical development of CoreMedic's transcatheter mitral valve repair device, ChordArt, which replaces damaged mitral valve chords in a minimally invasive procedure. The funding will also help prepare for the global expansion of a clinical program.

Browse the full report description of “Transcatheter Valve Market Size, Share & Trends Analysis Report by Application (Transcatheter Aortic Valve, Transcatheter Pulmonary Valve, and Transcatheter Mitral Valve), By Technology (Balloon-Expanded Transcatheter Valve, and Self-Expanded Transcatheter Valve) and By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), and Cardiac Catheterization Laboratories) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/transcatheter-valve-market

Recent Developments

• In March 2025, Boston Scientific invested $175 million in 4C Medical Technologies, a company focused on minimally invasive therapies for structural heart disease, to support a pivotal trial of their transcatheter mitral valve replacement device in the US and Europe.

• In January 2024, CardioMech raised $13 million to develop its transcatheter mitral valve repair technology for patients with degenerative mitral regurgitation. The artificial chord is designed to reduce or eliminate mitral regurgitation (MR), offering a non-invasive technique for younger, healthier patients without the need for open-heart surgery.

• In August 2022, JenaValve secured a $100 million Series C financing to advance its Trilogy TAVR solution, a treatment for high-surgical-risk patients with severe aortic regurgitation. The funding will enable JenaValve to complete the investigational device exemption premarket approval study and expand its manufacturing capabilities globally.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Application

o By Technology

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Abbott Laboratories, Boston Scientific Corp., Edwards Lifesciences Corp., Medtronic plc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Transcatheter Valve Market Report Segment

By Application

• Transcatheter Aortic Valve
• Transcatheter Pulmonary Valve
• Transcatheter Mitral Valve

By Technology

• Balloon Expanded Transcatheter Valve
• Self-Expanded Transcatheter Valve

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Cardiac Catheterization Laboratories

Global Transcatheter Valve Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/transcatheter-valve-market